Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-044106
Filing Date
2021-06-30
Accepted
2021-06-30 18:58:20
Documents
2
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5348
2 POA DOCUMENT poa.txt EX-24.3_996467 3534
  Complete submission text file 0001209191-21-044106.txt   10263
Mailing Address 4435 NORTH FIRST STREET, SUITE 360 LIVERMORE CA 94551
Business Address 4435 NORTH FIRST STREET, SUITE 360 LIVERMORE CA 94551 925-368-8508
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O PREVAIL THERAPEUTICS INC. 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address
Sevigny Jeffrey (Reporting) CIK: 0001778483 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40551 | Film No.: 211063378